NCT06569511View on ClinicalTrials.gov

Predictive Value of NT-proBNP on MACEs After Acute Coronary Syndrome

CompletedOBSERVATIONAL
Enrollment

241

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

February 1, 2024

Study Completion Date

March 1, 2024

Conditions
Acute Coronary SyndromeST-segment Elevation Myocardial Infarction (STEMI)Non-ST-Segment Elevation Myocardial Infarction (NSTEMI)Major Adverse Cardiac Events
Interventions
DIAGNOSTIC_TEST

N-terminal pro-B-type natriuretic peptide (NT-proBNP)

In patients diagnosed with Acute coronary syndrome, blood samples for serum NT-proBNP value were taken during transfer to the coronary intensive care unit

DIAGNOSTIC_TEST

high sensitive cardiac troponin T (hs-cTnT)

In patients diagnosed with Acute coronary syndrome, serum high-sensitive cardiac troponin T (hs-cTnT) levels were measured on admission to the Emergency Department.

Trial Locations (1)

34265

Haseki Training and Research Hospital, Istanbul

All Listed Sponsors
lead

Haseki Training and Research Hospital

OTHER

NCT06569511 - Predictive Value of NT-proBNP on MACEs After Acute Coronary Syndrome | Biotech Hunter | Biotech Hunter